# US 2003/0207940 A1 · Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0207940 A1
- Document ID: US20030207940A1
- Status: Published application
- Kind: A1
- Application number: 09/481,572
- Filed: 2000-01-11
- Published: 2003-11-06
- Earliest claimed: 2000-01-11
- Assignees: fx Life Sciences International GmbH
- Inventors: JACQUELINE J. SHAN; XI-CHEN WU; PETER K. T. PANG; LEI LING
- Web page: https://patentgrep.com/patent/US20030207940A1

## CPC

- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/12: Ketones
- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 36/38: Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Hypericin has been shown to specifically inhibited T-type calcium channel activity. Hypericum extract containing hypericin also inhibited T-type calcium channel activity. Moreover, other chemicals in Hypericum extract showed a synergistic effect to hypericin. In view of this, hypericin or hypericin-containing Hypericum extract can be used as T-channel blockers. Hypericum extract, extract of other species of the Hypericum genus, extract of other plants containing hypericin, hypericin, hypericin derivatives, hypericin analogs, such as pseudohypericin, and other hypericum extract constituents can be used as therapeutics targeted at T-type calcium channels for treatment of diseases associated with T-channel abnormality. Methods for administering hypericin and hypericum extract are disclosed.

## Claims

### Claim 1

A method of treating a health disorder treatable with a T-type calcium channel blocker in an animal in need of such a treatment, comprising administering an effective amount of an active agent to said animal, wherein said active agent is Hypericum perforatum, a Hypericum extract, an extract of a species of the Hypericum genus other than Hypericum perforatum, a Hypericum constituent, a hypericin derivative or a hypericin analog, with the proviso that when the active agent is Hypericum perforatum or Hypericum extract, said health disorder is not depression or migraine headache.

### Claim 2 (depends on 1)

The method of claim 1, wherein said hypericin derivative is a compound of formula II,
3
wherein
R1 is H, OH, OR or OCOR;
R2 is H, R, F, Cl, Br, I or SO3H;
R3 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R4 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R5 is H, R, F, Cl, Br, I or SO3H;
R6 is H, OH, OR or OCOR;
R7 is H, OH, OR or OCOR;
R8 is H, R, F, Cl, Br, I or SO3H;
R9 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R10 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R11 is H, R, F, Cl, Br, I or SO3H;
R12 is H, OH, OR or OCOR; and
R is an optionally substituted C1-C30 alkyl group;
with the proviso that the following compounds are excluded
(A) a compound of formula II, wherein R1, R3, R4, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, and R9 and R10 are methyl;
(B) a compound of formula II, wherein R1, R9, R10, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, and R3 and R4 are methyl;
(C) a compound of formula II, wherein R1, R3, R4, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R9 is methyl, and R1 is CH2OH;
(D) a compound of formula II, wherein R1, R3, R4, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R9 is CH2OH and R10 is methyl;
(E) a compound of formula II, wherein R1, R9, R10, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R3 is methyl, and R4 is CH2OH; and
(F) a compound of formula II, wherein R1, R9, R10, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R3 is CH2OH and R4 is methyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the health disorder treatable with T-type calcium channel blockers is depression, chronic heart failure, congestive heart failure, ischaemc condition, arrhythmia, angina pectoris, hypertension, hypoinsulinemia, hyperinsulinemia, diabete mellitus, hyperaldosteronemia, epilepsy, migraine headache, brain aging, a neurodegenerative disease or preterm labor.

### Claim 4 (depends on 1)

The method of claim 1, wherein said Hypericum constituent is hypericin, pseudohypericin, hyperforin, ashyperforin, quercetin, quercitrin, isoquercitrin, hyperoside, rutin, amentoflavone or hyperin.

### Claim 5 (depends on 2)

The method of claim 2, wherein R is a C1-C30 alkyl group, optionally substituted with one to three substituents independently selected from hydroxy, alkoxy, acyloxy, carboxy, akoxycarbonyl, amino, alkylamino, dialkylamino, nitro or phenyl group or fluorine, chlorine, bromine or iodine atom.

### Claim 6 (depends on 5)

The method of claim 5, wherein
R1 is H, OH, OR or OCOR;
R2 is H or R;
R3 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R4 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R5 is H or R;
R6 is H, OH, OR or OCOR;
R7 is H, OH, OR or OCOR;
R8 is H or R;
R9 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R10 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R11 is H or R;
R12 is H, OH, OR or OCOR; and
R is an optionally substituted C1-C6 alkyl group.

### Claim 7 (depends on 6)

The method of claim 6, wherein R is an optionally substituted methyl or ethyl group.

### Claim 8 (depends on 1)

The method of claim 1, wherein said animal is a human.

### Claim 9 (depends on 1)

The method of claim 1, wherein said active agent is a Hypericum extract.

### Claim 10 (depends on 9)

The method of claim 9, wherein said effective amount is about 0.05 mg to 500 mg per kg body weight of said animal.

### Claim 11 (depends on 1)

The method of claim 1, wherein said active agent is hypericin.

### Claim 12 (depends on 11)

The method of claim 11, wherein said effective amount is about 0.0015 mg to 15 mg per kg body weight of said animal.

### Claim 13 (depends on 1)

The method of claim 1, further comprising administering to said animal an additional active agent as described in claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein one of the active agents administered is hypericin.

### Claim 15 (depends on 14)

The method of claim 14, wherein another of the active agents administered is pseudohypericin.

### Claim 16 (depends on 14)

The method of claim 14, wherein another of the active agents administered is hyperforin.

### Claim 17 (depends on 15)

The method of claim 15, further comprising administering hyperforin to said animal.

### Claim 18

A compound of formula II,
4
wherein
R1 is H, OH, OR or OCOR;
R2 is H, R, F, Cl, Br, I or SO3H;
R3 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R4 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R5 is H, R, F, Cl, Br, I or SO3H;
R6 is H, OH, OR or OCOR;
R7 is H, OH, OR or OCOR;
R8 is H, R, F, Cl, Br, I or SO3H;
R9 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R10 is H, R, OH, OR, OCOR, CH2OH, CH2OR, CH2OCOR, COOH or COOR;
R11 is H, R, F, Cl, Br, I or SO3H;
R12 is H, OH, OR or OCOR; and
R is an optionally substituted C1-C30 alkyl group;
with the proviso that the following compounds are excluded
(A) a compound of formula II, wherein R1, R3, R4, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, and R9 and R10 are methyl;
(B) a compound of formula II, wherein R1, R9, R10, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, and R3 and R4 are methyl;
(C) a compound of formula II, wherein R1, R3, R4, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R9 is methyl, and R10 is CH2OH;
(D) a compound of formula II, wherein R1, R3, R4, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R9 is CH2OH and R10 is methyl;
(E) a compound of formula II, wherein R1, R9, R10, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R3 is methyl, and R4 is CH2OH;
(F) a compound of formula II, wherein R1, R9, R10, R6, R7 and R12 are OH, R2, R5, R8 and R11 are H, R3 is CH2OH and R4 is methyl.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R is a C1-C30 alkyl group, optionally substituted with one to three substituents independently selected from hydroxy, alkoxy, acyloxy, carboxy, akoxycarbonyl, amino, alkylamino, dialkylamino, nitro or phenyl group or fluorine, chlorine, bromine or iodine atom.

### Claim 20 (depends on 18)

The compound of claim 18, wherein
R1 is H, OH, OR or OCOR;
R2 is H or R;
R3 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R4 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R5 is H or R;
R6 is H, OH, OR or OCOR;
R7 is H, OH, OR or OCOR;
R8 is H or R;
R9 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R10 is H, OH, OR, OCOR, CH2OH, CH2OR or CH2OCOR;
R11 is H or R;
R12 is H, OH, OR or OCOR; and
R is an optionally substituted C1-C6 alkyl group.

### Claim 21 (depends on 20)

The compound of claim 20, wherein R is an optionally substituted methyl or ethyl group.

### Claim 22 (depends on 1)

The method of claim 1, wherein said extract of a species of the Hypericum genus other than Hypericum perforatum is an extract of a species selected from the group consisting of H. majus, H. formosum, H. calycinum, H. Xmoseranum, H. irazuense, H. reductum, H. patulum, H. mutilum, H. crux-andreae, H. hypericoides, H. densiflorum, H. prolificum, H. frondosum, H. cumilicola, H. anagalloides, H. androsaemum, H. tetrapterum, H. hirsutum, H. olympicum, H. hyssopifolium, H. elongatum and H. erratum.
